Study of RSS0343 in healthy adults
Part of Lungs & breathing clinical trials.
This study is testing a new medicine called RSS0343 in healthy volunteers to see how it is processed by the body and if it is safe. It is for healthy adults aged 18–55 who meet weight and health criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are generally healthy and between 18 and 55 years old.
- You weigh at least 110 pounds (for men) or 100 pounds (for women) and your body mass index (BMI) is between 19 and 28.
- If you are able to have children, you agree to use effective birth control for up to 6 months after the last dose.
- You do not smoke more than 5 cigarettes a day (or use other nicotine products) now or in the past 3 months.
- You do not have any serious medical conditions, allergies, or recent surgeries that could interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, HSK31858, for people with non-cystic fibrosis bronchiectasis (a lung condition causing chronic cough and infections). It aims to see if the drug reduces lung flare-ups and improves symptoms.
This study tests whether an investigational tablet called XH-S004 can reduce flare-ups and improve symptoms in people with bronchiectasis (widened airways that trap mucus). It is for adults who produce phlegm daily and have had at least two worsening episodes in the last year.
This trial tests an inhaled medication called CSL787 to see if it can help people with non-cystic fibrosis bronchiectasis (a lung condition that causes frequent infections and breathing problems). The study looks at different doses and checks how well the drug works and if it is safe.
This study tests how safe an experimental inhaled medicine (HSK31858) is for people with non-cystic fibrosis bronchiectasis, a lung condition where airways are damaged and collect mucus. You can only join if you already completed a previous HSK31858 study.
This study tests a new medication called Galvokimig to see if it helps reduce lung infections and improve quality of life in adults with bronchiectasis (a condition where lung airways are damaged and fill with mucus). It is a 24 to 52 week treatment, and you will be monitored closely for safety and effectiveness.
This trial tests an inhaled drug called ensifentrine in people with bronchiectasis (damaged, widened airways in the lungs). The goal is to see if it can reduce flare-ups and improve symptoms.
Hear when a new Non-cystic Fibrosis Bronchiectasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.